We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
TIDMGSK
RNS Number : 7867C
GlaxoSmithKline PLC
19 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') === =========================================================================== a) Name Ms E Walmsley === ======================== ================================================= b) Position/status Chief Executive Officer === ======================== ================================================= c) Initial notification/ Initial notification amendment === ======================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================= b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================= b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 575.028 ---------- ---------- === ======================== ================================================= d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================= e) Date of the transaction 2017-04-13 === ======================== ================================================= f) Place of the n/a transaction === ======================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === =========================================================================== a) Name Mr R G Connor === ======================== ================================================= b) Position/status President, Global Manufacturing & Supply === ======================== ================================================= c) Initial notification/ Initial notification amendment === ======================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================= b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================= b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 230.011 ---------- ---------- === ======================== ================================================= d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================= e) Date of the transaction 2017-04-13 === ======================== ================================================= f) Place of the n/a transaction === ======================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === =========================================================================== a) Name Mr S A Hussain === ======================== ================================================= b) Position/status President, Global Pharmaceuticals === ======================== ================================================= c) Initial notification/ Initial notification amendment === ======================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================= b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================= b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 287.514 ---------- ---------- === ======================== ================================================= d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================= e) Date of the transaction 2017-04-13 === ======================== ================================================= f) Place of the n/a transaction === ======================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr B McNamara === ======================== ================================================ b) Position/status CEO, GSK Consumer Healthcare === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of GlaxoSmithKline plc American Depositary the financial Shares ('ADSs') instrument ISIN: US37733W1053
=== ======================== ================================================ b) Nature of the Increase in notional interest in ADSs following transaction the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's Deferred Investment Award Programme. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $41.8150 359.648 --------- ---------- === ======================== ================================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================ e) Date of the transaction 2017-04-13 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === =========================================================================== a) Name Mr D S Redfern === ======================== ================================================= b) Position/status Chief Strategy Officer === ======================== ================================================= c) Initial notification/ Initial notification amendment === ======================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================= b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================= b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 230.011 ---------- ---------- === ======================== ================================================= d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================= e) Date of the transaction 2017-04-13 === ======================== ================================================= f) Place of the n/a transaction === ======================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Ms C Thomas === ======================== ================================================ b) Position/status Senior Vice President, HR === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 230.011 ---------- ---------- === ======================== ================================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================ e) Date of the transaction 2017-04-13 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Dr P J T Vallance === ======================== ================================================ b) Position/status President, R&D === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.39 287.514 ---------- ---------- === ======================== ================================================ d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== ================================================ e) Date of the transaction 2017-04-13 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHQKLFFDZFXBBQ
(END) Dow Jones Newswires
April 19, 2017 12:38 ET (16:38 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions